Eli Lilly and Company

Dowelanco

Otis W., Jr. Godfrey

Tom E. Eaton

Hang Chio

Laverne D. Boeck

Karl H. Michel

Raymond C. Yao

Walter M. Nakatsukasa

Karl H Michel

Marvin M Hoehn

LaVerne D Boeck

Raymond C Yao

Ralph E Kastner

Calvin E Higgens

Otis W Godfrey

Marie T Anderson

Walter M Nakatsukasa

Tom E Eaton

Gladys M Clem

Charles L Hershberger

Herbert A Kirst

Milton J Zmijewski

Jeffrey T Fayerman

Michael D Jones

Thomas H Sands

Robert F Miller

Laverne D Boeck

Jr Godfrey Otis W

Fermentation product A83543, comprising major components A83543A and A83543D and minor components A83543B, A83543C, A83543E, A83543F, A83543G, A83543H and A83543J, is produced by a newly described species, Saccharopolyspora spinosa. The A83543 components and their acid-addition salts (A83543 compounds) are useful as insecticides, particularly against Lepidoptera and Diptera species. Insecticidal, miticidal or ectoparasiticidal combinations, compositions and methods are provided.

Insecticide and miticide compositions containing A83543 compounds

Fermentation product A83543, comprising major components A83543A and A83543D and minor components A83543B, A83543C, A83543E, A983543F, A83543G, A83543H and A83543J, is produced by a newly described species, Saccharopolyspora spinosa. The A83543 components and their acid-addition salts (A83543 compounds) are useful as insecticides, particularly against Lepidoptera and Diptera species. Insecticidal, miticidal or ecto-parasiticidal combinations, compositions and methods are provided.

Insecticide and miticide A83543 compounds and their method of production

Process for producing A83543 compounds

Newly discovered lipoglycopeptide antibiotic A84575 complex, comprising factors A, B, C, D, E, F, G, and H, is produced by submerged aerobic fermentation of a culture selected from Streptosporangeum carneum NRRL 18437, Streptosporangeum carneum NRRL 18505 or an A84575-producing mutant thereof. The antibiotics are active against Gram-positive bacteria.

A84575 antibiotics

Newly-discovered antibiotic A10255 factors B, C, E, and F are produced by submerged aerobic fermentation of previously-unknown Streptomyces gardneri strain NRRL 15922, or an A10255-producing variant, mutant or recombinant thereof. The antibiotics are active against a wide variety of pathogenic bacteria, and also enhance feed-utilization efficiency in chickens, weanling pigs and cattle.

Process for producing the A10255 complex and corresponding microorganism

A novel antibiotic complex, A59770, individual factors and derivatives thereof, are provided. The A59770 compounds are useful as pesticides, particularly as rodenticides. Further provided are methods for reducing a rodent population, rodenticidal compositions, and an A59770-producing Amycolatopsis orientalis culture.

A59770 antibiotics

Newly-discovered antibiotic A10255 factors B, C, E, F, G, H, and J are produced by submerged aerobic fermentation of Streptomyces gardneri NRRL 15537 and NRRL 18260 or an A10255-producing variant or mutant thereof. The antibiotics are active against a wide variety of pathogenic bacteria, and also enhance feed-utilization efficiency in chickens, weanling pigs, cattle and sheep. The antibiotics can also be used to detect the thiostrepton-resistance gene in Streptomyces species.

Antibiotic A10255 complex and factors, and process and production

Improved fermentation process for producing the Gram-positive antibiotic A47934 which comprises cultivating a new strain of Streptomyces toyocaensis, NRRL 18112, and a biologically purified culture of this microorganism are provided.

Process for producing antibiotic A47934

Antibiotic A41030, a complex of 7 individual factors, is produced by submerged, aerobic fermentation of new Streptomyces virginiae NRRL 12525, and Streptomyces virginiae NRRL 15156. The antibiotic factors are separated and possess antibacterial activity against Staphylococcus and Streptococcus species which are penicillin resistant. In addition, the antibiotic factors have shown inhibition of Streptococcus pneumonia Park I. The complex and the individual factors enhance feed efficiency in ruminant animals, and are growth promoters in chickens and swine, and are especially valuable in milk production in dairy cattle.

Microbial production of A41030 antibiotics

New glycopeptide antibiotic CUC/CSV which has the formula: ##STR1## wherein R is L-ristosaminyl;

Glycopeptide antibiotic CUC/CSV and process for its production

Antibiotics

New glycopeptide antibiotics of the formula: ##STR1## wherein W is the remaining portion of a glycopeptide antibiotic selected from actaplanin factors B.sub.1, B.sub.2, B.sub.3, C.sub.1, C.sub.2, C.sub.3, D.sub.1, D.sub.2, E.sub.1, G, K, L, M, N, O and actaplanin .psi.aglycone, and salts thereof, particularly the pharmaceutically acceptable salts, are useful new antibiotics are active against gram-positive bacteria and increase feed-efficiency utilization and enhance milk production in ruminants.

Glycopeptide bioconversion products

A41030 Antibiotics

Antibiotics M43B and M43C, new glycopeptide antibiotics of the vancomycin class, are produced by Nocardia orientalis NRRL 2452. M43B and M43C have antibacterial activity.

Antibiotics M43B and M43C, pharmaceutical composition and method of use

Antibiotic A41030, a complex of 7 individual factors, is produced by submerged, aerobic fermentation of new Streptomyces virginiae NRRL 12525, and Streptomyces virginiae NRRL 15156. The antiobiotic factors are separated and possess antibacterial activity against Staphylococcus and Streptococcus species which are penicillin resistant. In addition, the antibiotic factors have shown inhibition of Streptococcus pneumonia Park I. The complex and the individual factors enhance feed efficiency in ruminant animals, and are growth promoters in chickens and swine, and are especially valuable in milk production in dairy cattle.

Growing community of inventors

Indianapolis, IN, United States of America

Karl H Michel